Xavier Badia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xavier Badia has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Montserrat Roset
Catalan Institute of Public Health, University of Barcelona, Spain
10 shared publications N Perulero
5 shared publicationsM Cucala
3 shared publicationsA Benavides
2 shared publicationsE Domínguez
2 shared publicationsF Mearín
2 shared publications
Latest Publications
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A484
Mapping Acroqol Scores to EQ-5D to Obtain Utility Values for Patients with Acromegaly
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A484
Mapping Acroqol Scores to EQ-5D to Obtain Utility Values for Patients with Acromegaly
- 1 May 2013
- Published by Elsevier in Value in Health
- Vol. 16 (3) , A167
Burden of acromegaly– A retrospective chart audit
- 1 May 2013
- Published by Elsevier in Value in Health
- Vol. 16 (3) , A167
Burden of acromegaly– A retrospective chart audit
- 1 November 2011
- Published by Elsevier in Value in Health
- Vol. 14 (7) , A541
PR1 Responsiveness of the Copd Assessment Test (CAT) Questionnaire During Exacerbations of COPD
- 1 November 2011
- Published by Elsevier in Value in Health
- Vol. 14 (7) , A541
PR1 Responsiveness of the Copd Assessment Test (CAT) Questionnaire During Exacerbations of COPD
- 31 October 2009
- Published by Elsevier in Value in Health
- Vol. 12 (7) , A458
PSS33 DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTHRELATED QUALITY OF LIFE IN PATIENTES WITH PSOARIASIS: ‘PSO-LIFE’
- 31 October 2009
- Published by Elsevier in Value in Health
- Vol. 12 (7) , A458
PSS33 DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTHRELATED QUALITY OF LIFE IN PATIENTES WITH PSOARIASIS: ‘PSO-LIFE’
- 31 December 2007
- Published by Elsevier in Value in Health
- Vol. 10 (6) , A470
PSK8 ASSESSMENT OF INVOLVED BODY SURFACE AREA (BSA) IN PSORIASIS PATIENTS. VALIDATION OF SOFTWARE ASSISTED DIAGNOSIS BSA FOR THE MANAGEMENT OF PSORIASIS
- 31 December 2007
- Published by Elsevier in Value in Health
- Vol. 10 (6) , A470
PSK8 ASSESSMENT OF INVOLVED BODY SURFACE AREA (BSA) IN PSORIASIS PATIENTS. VALIDATION OF SOFTWARE ASSISTED DIAGNOSIS BSA FOR THE MANAGEMENT OF PSORIASIS
- 31 December 2006
- Published by Elsevier in Value in Health
- Vol. 9 (6) , A309
PIN32 VALIDATION OF THE PATIENTS' ATTITUDES AND PERCEPTIONS TOWARDS HAART QUESTIONNAIRE
- 31 December 2006
- Published by Elsevier in Value in Health
- Vol. 9 (6) , A309
PIN32 VALIDATION OF THE PATIENTS' ATTITUDES AND PERCEPTIONS TOWARDS HAART QUESTIONNAIRE
- 1 February 2006
- Published by Elsevier in Revista Española de Enfermedades Metabólicas Óseas
- Vol. 15 (1) , 1-7
Las preocupaciones en salud de las mujeres con osteoporosis; su satisfacci n y adherencia al tratamiento
- 1 February 2006
- Published by Elsevier in Revista Española de Enfermedades Metabólicas Óseas
- Vol. 15 (1) , 1-7
Las preocupaciones en salud de las mujeres con osteoporosis; su satisfacci n y adherencia al tratamiento
- 31 December 2005
- Published by Elsevier in Value in Health
- Vol. 8 (6) , A61-A62
PIN20 STUDYVALIDATION OF QUALITY OF LIFE QUESTIONNAIRE MINI-HIV
- 31 December 2005
- Published by Elsevier in Value in Health
- Vol. 8 (6) , A61-A62
PIN20 STUDYVALIDATION OF QUALITY OF LIFE QUESTIONNAIRE MINI-HIV
- 1 August 2004
- Published by SAGE Publications in Antiviral Therapy
- Vol. 9 (6) , 979-985
Health-Related Quality of Life in HIV Patients Switching to Twice-Daily Indinavir/Ritonavir Regimen or Continuing with Three-Times-Daily Indinavir-Based Therapy
Objective: To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen. Methods: Patients on HAART including indinavir three-times-daily with undetectable viral load were randomly assigned to continue with this therapy or to change to a twice-daily indinavir/ritonavir (800/100 mg) regimen. The Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaire was used as the HRQoL measure. Results: A total of 118 patients participated in the study, of which 59 (50%) were randomly assigned to continue with the three-times-daily regimen. Patients had a mean age of 39 years and 80% of them were male. At baseline, subjects included in the three-times-daily group presented a significantly greater number of symptoms than subjects in the twice-daily group, but no statistically significant differences were observed in MOS-HIV scores between the groups. In the intention-to-treat (ITT) analysis, a reduction in HRQoL scores was observed in both groups, which was greater in the twice-daily group. In the per protocol analysis, reduction of HRQoL was minimal. Conclusions: A HRQoL deterioration, greater in the twice-daily group, was observed in this study in the ITT analysis, while HRQoL remained stable in both groups in patients who continued with and tolerated the allocated regimen.
- 1 August 2004
- Published by SAGE Publications in Antiviral Therapy
- Vol. 9 (6) , 979-985
Health-Related Quality of Life in HIV Patients Switching to Twice-Daily Indinavir/Ritonavir Regimen or Continuing with Three-Times-Daily Indinavir-Based Therapy
Objective: To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen. Methods: Patients on HAART including indinavir three-times-daily with undetectable viral load were randomly assigned to continue with this therapy or to change to a twice-daily indinavir/ritonavir (800/100 mg) regimen. The Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaire was used as the HRQoL measure. Results: A total of 118 patients participated in the study, of which 59 (50%) were randomly assigned to continue with the three-times-daily regimen. Patients had a mean age of 39 years and 80% of them were male. At baseline, subjects included in the three-times-daily group presented a significantly greater number of symptoms than subjects in the twice-daily group, but no statistically significant differences were observed in MOS-HIV scores between the groups. In the intention-to-treat (ITT) analysis, a reduction in HRQoL scores was observed in both groups, which was greater in the twice-daily group. In the per protocol analysis, reduction of HRQoL was minimal. Conclusions: A HRQoL deterioration, greater in the twice-daily group, was observed in this study in the ITT analysis, while HRQoL remained stable in both groups in patients who continued with and tolerated the allocated regimen.
- 1 June 2004
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 5 (3) , 132-139
Health-Related Quality of Life in HIV-Infected Naive Patients Treated with Nelfinavir or Nevirapine Associated with ZDV/3TC (the COMBINE-QoL Substudy)
Purpose: The aim of the study was to assess differences in health-related quality of life (HRQoL) in HIV-infected naive patients treated with two HAART regimens at 12 months. Method: The MOS-HIV questionnaire was used to measure HRQoL in a subgroup of 127 patients included in the COMBINE study, which was an open-label, randomized, multicenter study comparing zidovudine (ZDV) and lamivudine (3TC) plus nelfinavir (NFV) or nevirapine (NVP) regimens in HIV-infected naive patients. 63 patients were included in the ZDV/3TC/NFV arm and 64 in the ZDV/3TC/NVP arm. Results: No statistically significant differences were observed at baseline in demographic and clinical variables and HRQoL scores between treatment groups, except that the proportion of homosexual men was higher in the ZDV/3TC/NVP arm. There were no statistically significant differences in HRQoL scores between arms at 12 months and over time; only ZDV/3TC/NVP patients showed statistically significant improvement in Physical Health Summary score (p < .01) and a trend toward a better profile in Mental Health Summary score (p = .07). Overall, patients who were treated with ZDV/3TC/NVP showed greater changes in physical dimensions and patients who were treated with ZDV/3TC/NFV showed greater changes in mental health. Conclusion: Differences in HRQoL between study groups at 1 year follow-up were not detected. Nevertheless, a trend toward improvement was observed in summary health scores in ZDV/3TC/NVP-treated patients.
- 1 June 2004
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 5 (3) , 132-139
Health-Related Quality of Life in HIV-Infected Naive Patients Treated with Nelfinavir or Nevirapine Associated with ZDV/3TC (the COMBINE-QoL Substudy)
Purpose: The aim of the study was to assess differences in health-related quality of life (HRQoL) in HIV-infected naive patients treated with two HAART regimens at 12 months. Method: The MOS-HIV questionnaire was used to measure HRQoL in a subgroup of 127 patients included in the COMBINE study, which was an open-label, randomized, multicenter study comparing zidovudine (ZDV) and lamivudine (3TC) plus nelfinavir (NFV) or nevirapine (NVP) regimens in HIV-infected naive patients. 63 patients were included in the ZDV/3TC/NFV arm and 64 in the ZDV/3TC/NVP arm. Results: No statistically significant differences were observed at baseline in demographic and clinical variables and HRQoL scores between treatment groups, except that the proportion of homosexual men was higher in the ZDV/3TC/NVP arm. There were no statistically significant differences in HRQoL scores between arms at 12 months and over time; only ZDV/3TC/NVP patients showed statistically significant improvement in Physical Health Summary score (p < .01) and a trend toward a better profile in Mental Health Summary score (p = .07). Overall, patients who were treated with ZDV/3TC/NVP showed greater changes in physical dimensions and patients who were treated with ZDV/3TC/NFV showed greater changes in mental health. Conclusion: Differences in HRQoL between study groups at 1 year follow-up were not detected. Nevertheless, a trend toward improvement was observed in summary health scores in ZDV/3TC/NVP-treated patients.